Status:
COMPLETED
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
Eligibility Criteria
Inclusion
- Diagnosis of probable AD according to the NINCDS-ADRDA criteria.
- Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive.
- Able to give informed consent. Patient's caregiver must consent to participate in the study.
Exclusion
- Significant neurologic disease other than AD that may affect cognition.
- Current clinically significant systemic illness which is likely to deteriorate or affect the subject's safety during the study.
- Other exclusions apply
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00151333
Start Date
February 1 2005
End Date
April 1 2005
Last Update
September 4 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85013
2
Fort Lauderdale, Florida, United States, 33321
3
Miami, Florida, United States, 33154